These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28478716)

  • 1. Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial.
    Ahmadi M; Khalili H; Abbasian L; Ghaeli P
    Ann Pharmacother; 2017 Jun; 51(6):457-464. PubMed ID: 28478716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
    Dabaghzadeh F; Ghaeli P; Khalili H; Alimadadi A; Jafari S; Akhondzadeh S; Khazaeipour Z
    AIDS Patient Care STDS; 2013 Mar; 27(3):146-54. PubMed ID: 23442031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
    Gutiérrez-Valencia A; Viciana P; Palacios R; Ruiz-Valderas R; Lozano F; Terrón A; Rivero A; López-Cortés LF;
    Ann Intern Med; 2009 Aug; 151(3):149-56. PubMed ID: 19581631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
    ; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
    Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
    Nelson M; Stellbrink HJ; Podzamczer D; Banhegyi D; Gazzard B; Hill A; van Delft Y; Vingerhoets J; Stark T; Marks S
    AIDS; 2011 Jan; 25(3):335-40. PubMed ID: 21150563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
    Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
    HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.
    ENCORE1 Study Group
    Lancet; 2014 Apr; 383(9927):1474-1482. PubMed ID: 24522178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.
    Gaida R; Truter I; Grobler C; Kotze T; Godman B
    Expert Rev Anti Infect Ther; 2016; 14(4):377-88. PubMed ID: 26900637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
    Fätkenheuer G; Duvivier C; Rieger A; Durant J; Rey D; Schmidt W; Hill A; van Delft Y; Marks S;
    J Antimicrob Chemother; 2012 Mar; 67(3):685-90. PubMed ID: 22210755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom.
    Law JKC; Butler LT; Hamill MM
    AIDS Res Hum Retroviruses; 2020 Jun; 36(6):459-466. PubMed ID: 31931589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
    Leutscher PD; Stecher C; Storgaard M; Larsen CS
    Scand J Infect Dis; 2013 Aug; 45(8):645-51. PubMed ID: 23427878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia.
    Jacobs BP; Bent S; Tice JA; Blackwell T; Cummings SR
    Medicine (Baltimore); 2005 Jul; 84(4):197-207. PubMed ID: 16010204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.
    Clifford DB; Evans S; Yang Y; Acosta EP; Goodkin K; Tashima K; Simpson D; Dorfman D; Ribaudo H; Gulick RM
    Ann Intern Med; 2005 Nov; 143(10):714-21. PubMed ID: 16287792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.
    Dabaghzadeh F; Khalili H; Ghaeli P; Dashti-Khavidaki S
    Expert Opin Pharmacother; 2012 Dec; 13(18):2613-24. PubMed ID: 23140169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
    Pedrol E; Llibre JM; Tasias M; Currán A; Guardiola JM; Deig E; Guelar A; Martínez-Madrid O; Tikhomirova L; Ramírez R;
    HIV Med; 2015 Nov; 16(10):628-34. PubMed ID: 26238151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
    Waters L; Fisher M; Winston A; Higgs C; Hadley W; Garvey L; Mandalia S; Perry N; Nicola M; Nelson M
    AIDS; 2011 Jan; 25(1):65-71. PubMed ID: 21099666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
    HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events.
    Ibarra-Barrueta O; Palacios-Zabalza I; Mora-Atorrasagasti O; Mayo-Suarez J
    Ann Pharmacother; 2014 Jan; 48(1):145-8. PubMed ID: 24259633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.